Lynch syndrome is the most common hereditary colorectal cancer (CRC) syndrome and accounts for 1-5% of all CRCs. Also known as hereditary nonpolyposis colorectal cancer (HNPCC), Lynch syndrome is characterized by a marked increase in lifetime risk of early-onset CRC as well as increased risk of other malignancies, including cancers of the endometrium, stomach, ovary, urinary tract, and brain (1) . Inherited mutations in DNA mismatch repair (MMR) genes, most commonly MLH1 and MSH2, but also MSH6 and PMS2, underlie the genetic basis of Lynch syndrome (1) . Germline mutations in the MMR genes result in the accumulation of mutations during DNA replication, particularly in repetitive sequences known as microsatellites. This microsatellite instability (MSI) is a hallmark of tumors associated with Lynch syndrome. Loss of expression of the MMR proteins can be detected by immunohistochemical (IHC) analysis of the four MMR genes. Approximately 15% of sporadic cases also exhibit MSI; inclusion of BRAF mutation and MLH1 promoter analyses on tumor tissue identifies sporadic MSI-positive tumors and thereby may prevent unnecessary genetic evaluations (2) .
Although germline genetic testing can identify mutationpositive individuals, sequencing of the MMR genes is currently much too time-consuming, difficult, and expensive to be feasible for all CRC patients. However, it is of critical importance to distinguish CRC due to Lynch syndrome from sporadic cases (or other hereditary syndromes), because appropriate clinical management and increased surveillance significantly reduces cancer incidence and mortality for both the patient and any mutation-positive relatives (3). Asymptomatic individuals with Lynch syndrome mutations require colonoscopies every 1-2 yr starting at age 20-25, screening for gynecologic and other tumors, as well as consideration of prophylactic surgery (4, 5) .
Historically, diagnosis of Lynch syndrome relied on clinical characteristics of personal and family history of cancer. The Amsterdam criteria (6), later revised to Amsterdam II criteria (7), classically defined Lynch syndrome, but are now well-recognized to be too stringent and insufficiently sensitive. With the availability of molecular diagnostic testing, the Bethesda Guidelines (8) , later updated to the Revised Bethesda Guidelines (9), were developed to select patients who should undergo MSI analysis. Recently, several prediction models (10) (11) (12) have been published to quantify the risk of being a mutation carrier and increase identification rate of Lynch syndrome patients; however, their usefulness in the general population still needs to be evaluated.
In an effort to improve the detection rate of Lynch syndrome individuals, it has been suggested that the tumors of all CRC patients be assessed by MSI analysis or IHC instead of relying on clinical guidelines to select patients for germline analysis. In this issue of American Journal of Gastroenterology, the article by Julie et al. (13) addresses the important issue of determining an optimal strategy for identifying Lynch syndrome patients. The authors compare the performance of the Revised Bethesda Guidelines and a universal molecular strategy for identifying patients with Lynch syndrome from among 214 newly diagnosed CRC patients. All tumor samples were evaluated by MSI analysis and those that were MSI positive were further analyzed by IHC. Patients with MSI positive tumors received germline testing guided by the IHC assessment. A total of eight patients were determined to harbor pathogenic mutations in one of the four MMR genes assessed. The authors compared the Revised Bethesda Guidelines to the original Bethesda Guidelines and the original and revised Amsterdam criteria. The Revised Bethesda Guidelines followed by MSI analysis performed the best and identified 42.1% of patients for MSI testing, of which 4.2% were MSI positive and six were MMR mutation-positive. However, this strategy was less sensitive than a molecular strategy of universal MSI testing followed by BRAF mutation analysis and MLH1 promoter analysis. The molecular strategy identified 9.8% of patients as MSI positive and, after BRAF and MLH1 promoter methylation analysis to exclude MSIpositive sporadic cancers, 5.1% of patients for germline assessment to detect all eight MMR mutation positive patients. Thus, the authors conclude that the Revised Bethesda Guidelines do not adequately identify mutation carriers and that the proposed molecular strategy would better detect Lynch syndrome individuals with minimal additional workload.
Few previous studies have examined the performance of the clinical guidelines or compared their effectiveness of identifying Lynch syndrome positive patients to that of universal molecular diagnostic testing strategies in an unselected population of CRC patients. It is noteworthy that, like Julie et al. (13) , a recent study also concluded that BRAF analysis should be included in any molecular screening algorithm for Lynch syndrome (14) . An evaluation of the Revised Bethesda Guidelines in a population-based cohort of CRC patients from the Spanish EPICOLON study demonstrated that these and the original Bethesda Guidelines, as well as universal molecular testing strategies evaluating MSI and loss of MMR protein expression, were 100% effective in identifying patients with Lynch syndrome mutations (15, 16) . However, another study of unselected CRC patients in the U.S. suggested that a universal testing strategy based on MSI or IHC testing was more effective than a combined criteria of original and Revised Bethesda Guidelines for identifying patients who were MMR mutation-positive (17) . It must be noted though, that the reported missed detection rate of the Bethesda Guidelines in the latter study may be artificially high because these authors were only able to assess first-degree relatives and might have missed relevant cancer history in second-degree relatives that would result in fulfillment of the clinical criteria. Therefore, the results by Julie et al. (13) are similar to some studies supporting a universal molecular testing strategy for identifying Lynch syndrome patients (15-17), but conclusions diverge from those made in the EPICOLON study where the clinical criteria also performed as well as the universal molecular strategy. A number of reasons could account for this difference including the number of MMR genes evaluated (two in the Spanish study compared to four in the present study), different number of markers used to evaluate MSI, and natural population variation. Another point of interest is that in both the EPICOLON and Julie et al. (13) studies, similar proportions of the patient population fulfilled original Bethesda Guidelines (approximately 18%), but the prevalence of fulfilling the revised criteria in the current study was almost twice that of the EPICOLON study (42.1% compared to 23.5%). It is not clear what contributes to this difference though the EPICOLON study reported only 0.9% MMR positive patients compared to 3.7% in the present study. It is particularly notable that the two mutation-positive patients undetected by the Revised Bethesda Guidelines in the study by Julie et al. (13) had no (or limited) family histories of cancer and cancer diagnoses in the proband at a much later age than is typical for Lynch syndrome patients. Although the authors report that they gathered extensive family history on each of these two individuals, the histories are so atypical for Lynch syndrome that one wonders about accuracy of reporting or other issues such as nonpaternity that may be playing a role.
It is important to note here that when assessing various approaches for identifying Lynch syndrome patients, comparison of strategies is complicated by methodological issues for measurement of sensitivity and specificity. In populationbased studies to date including the present one by Julie et al. (13) , likely due to a number of factors such as prohibitive costs, not all study subjects are assessed by the gold standard of germline DNA analysis. Therefore, the true sensitivity and specificity of investigated strategies are unknown. As the prevalence of Lynch syndrome-positive patients in these studies are determined by germline evaluation of patients whose tumors were MSI positive (or demonstrated loss of MMR gene product), by default, the sensitivity of a universal molecular strategy based on the molecular diagnostic test which identified patients for genetic testing will be biased and misleadingly be 100%. Ultimately, the ideal study would be a large population-based study of newly diagnosed CRC patients comparing various screening techniques (both clinically-based and molecular testing techniques) with full gene sequencing for all study subjects. In addition, rigorous, updated cost-effectiveness studies are needed to evaluate which strategy would be the most valuable use of limited health care dollars.
Until these studies are available, what should be done? Should clinical guidelines continue to be the basis for identification of Lynch syndrome patients, or should universal molecular diagnostic testing become standard of care? Based on the aggregate currently available literature, there is insufficient evidence to support a universal molecular testing strategy for all CRC patients, and most pathology labs are not routinely doing MSI and IHC analysis (i.e., without a specific request by the treating physician), even for the subset of patients who fulfill the Bethesda Guidelines. Unfortunately, there is also ample evidence that the clinical guidelines are not being widely implemented by physicians to identify CRC patients who should be evaluated for Lynch syndrome (18) (19) (20) .
Given current data and the Bethesda Guideline recommendations, we have recently implemented a system centered in our pathology department that will flag every CRC specimen from a patient under age 50 to undergo both MSI and IHC testing in an attempt to systematically identify Lynch syndrome-positive individuals in this subset of patients at our institution. BRAF analysis will be done on the tumors of all patients with the MSI phenotype and loss of MLH1 expression. The pathology report of individuals who have MSI or IHC abnormalities will include a recommendation for genetic counseling and contact information regarding how to set up an appointment. Implementation of this strategy required agreement by our gastroenterologists, oncologists, surgeons, and pathologists, who all felt comfortable that (i) there was sufficient evidence to proceed with routine molecular testing in this age group of CRC patients, and (ii) performing MSI and IHC tumor testing was somatic analysis that did not fall into the same rubric as germline genetic tests, and therefore did not require informed consent by the patient. We will closely monitor this newly implemented strategy to assess its effectiveness for identifying patients eligible for germline testing and determine whether this leads to increased compliance of genetic testing for Lynch syndrome.
There are a few other institutions with a routine molecular testing policy for certain patient groups, but others have decided against this for a number of reasons, including cost and potential ethical dilemmas surrounding privacy and discrimination issues and concerns about whether informed consent is necessary before proceeding to tumor testing. It is also important to realize that routine tumor testing does not solve the issue of identifying patients who have never had cancer, but are at risk for Lynch syndrome because of a positive family history. To adequately identify these patients, systematic efforts need to be made to obtain cancer family histories of patients in primary care and gastroenterology clinics as well as direct access endoscopy suites and refer those who meet guidelines.
In summary, the optimal strategy for identifying Lynch syndrome patients likely consists of both methodological clinical criteria assessment of all patients for related malignancies, and systematic molecular diagnostic testing for a subset of high-risk individuals. Although there is insufficient evidence to recommend universal molecular testing and there is no identified optimal strategy right now, what is most urgently needed is a change in the current standard of care to implement some form of systematic screening for the disease. Physicians and health care systems can better utilize existing guidelines so that we can increase identification of Lynch syndrome families who will benefit from appropriate clinical management.
